Read also: Malaria: Niger gives its “green light” to the vaccination of children under 5 According to him, a 70% reduction in malaria deaths could be achievable within that time frame, in part thanks to the large number of vaccine doses that could be produced quickly. “We could see a very substantial reduction in this horrible burden of malaria, a reduction in deaths and illnesses in the years to come, certainly by 2030”, said Adrian Hill, a vaccine specialist at Oxford and co-author of the study. “I can therefore confirm that R21 is much more effectivehe said at a press conference.
#Irss canada trial
Mr Tinto, who was involved in the trial of both malaria vaccines, said GSK’s vaccine had an optimal efficacy of around 60%.
“It’s fantastic to see such high efficacy after a single booster dose”, welcomed one of the authors of the study, Halidou Tinto, of the Burkina Faso Health Research Institute (IRSS). Importantly, one month after receiving the booster, antimalarial antibodies returned to a level similar to that seen after the first doses received a year earlier, according to the study. For the lowest dose, the efficacy was 70%. For the group that received the highest dose of adjuvant, the effectiveness of the vaccine increased to 80%, according to the results of a phase 2 trial published Thursday. They were divided into three groups: two received different doses of the Matrix-M adjuvant, a vaccine ingredient patented by Novavax and also used in the American biotechnology company’s Covid-19 vaccine the third control group received a rabies vaccine.īefore the 2020 rainy season (when malaria cases increase), 409 children returned for a booster shot.
Read also: Article reserved for our subscribers “Every minute, a child under the age of 5 dies of malaria in the world”įor the study, 450 children aged 5 to 17 months in Burkina Faso – where malaria accounts for around 22% of all deaths – received three doses in 2019. This is the first time that a vaccine has exceeded the efficacy target set by the WHO at 75%. Oxford’s R21/Matrix-M vaccine was found to be 77% effective in preventing malaria, according to a study published last year.
But research has shown that the effectiveness of GSK’s vaccine is around 60% and drops dramatically over time, even with a booster dose.
It has since been given to more than one million children in Africa. Last year another vaccine, produced by British pharmaceutical giant GSK, became the first malaria vaccine to be recommended for widespread use by the World Health Organization (WHO). Malaria, a parasitic disease transmitted by mosquitoes, killed 627,000 people – mostly African children – in 2020 alone. This vaccine, developed by scientists at the University of Oxford, could represent a turning point in the fight against the disease, the researchers said. BAZ RATNER / REUTERSĪ booster dose of a new malaria vaccine maintains a high level of protection against the disease, assured an international research team, Thursday September 8 in the journal Lancet Infectious Diseases, raising hopes that this inexpensive vaccine could be produced on a large scale in a few years. A nurse prepares a dose of malaria vaccine at a hospital in Kisumu, Kenya on July 1, 2022.
0 kommentar(er)
